The U.S. Food and Drug Administration (FDA) provided feedback to uniQure N.V. (NASDAQ:QURE) regarding its investigational gene therapy for Huntington’s disease, causing the stock to decline on Monday.QURE is encountering selling pressure. Find out why hereThe company received FDA feedback during a recent pre-Biologics License Application (BLA) meeting regarding AMT-130, an investigational gene therapy for Huntington’s disease (HD). uniQure believes that the FDA currently disagrees that the data from the Pha ...